Optimization of the pharmacological component using additive placeboeffects: Is it possible to enhance the psychological component during self-medication by disclosing information about the psychological components
Not Applicable
Suspended
- Conditions
- self-medication: participants using a specific analgesic (ibuprofen, paracetamol, aspirin) for pain relief self-medication: participants using a specific antihistamine (dimetindene, loratadine, cetirizine) for itch relief
- Registration Number
- DRKS00009506
- Lead Sponsor
- niversitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
self-medication with an antihistamine (dimetindene/cetirizine/loratadine) to reduce itch intensity or selfmedication with an analgesic (ibuprofen/aspirin,paracetamol) to reduce pain
Exclusion Criteria
- symptom intensity < 3 on a numeric rating scale (range 0 to 10)
- acute and/or chronic psychiatric disorders (ICD-10) according to participant's statement
- poor knowledge of the German language
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoints are the symptom reduction (numeric rating scale), medication intake and related side-effects collected via an online survey and a possible paper version (including STAI-S (anxiety), SETS (Stanford Expectations of Treatment Scale; measuring patient outcome expectancy in clinical trials ), PHQ-4 (anxiety and depression) at three points of time: baseline, post1 (after intervention) and post2 (couse over seven days).
- Secondary Outcome Measures
Name Time Method